Bristol-Myers Squibb (BMY.N) announced on Sunday that it has agreed to buy Mirati Therapeutics (MRTX.O), a cancer drugmaker with a portfolio of drugs that target the genetic drivers of specific cancers. The deal is worth up to $5.8 billion, including cash and contingent value rights. The acquisition will diversify Bristol’s oncology business and add drugs…